Literature DB >> 23277038

Role of innate immunity in cardiac inflammation after myocardial infarction.

Lucas Liaudet1, Nathalie Rosenblatt-Velin.   

Abstract

Over the past two decades, inflammation has emerged as a key pathophysiological process during myocardial infarction. It develops consecutively to the activation of innate immune defense mechanisms, in response to the release of endogenous molecules by necrotic cells and the extracellular matrix. These danger signals are sensed by cellular receptors normally involved in antimicrobial defenses, including toll-like receptors and a subset of NOD-like receptors, which promote intracellular signaling dependent on nuclear factor kappaB and on the formation of the inflammasome. These mechanisms stimulate the expression of multiple inflammatory mediators and growth factors, sequentially inducing the recruitment of inflammatory cells, the clearance of injured tissue, angiogenesis, and the proliferation of fibroblasts, eventually resulting in scar formation and infarct healing. Dysregulation of these responses may result in continued cardiomyocyte loss, fibrosis beyond the limits of the infarcted area, reactive hypertrophy and chamber dilatation, a process termed adverse cardiac remodeling, leading to functional compromise and heart failure. This review presents the current state of knowledge on the process of immune activation within the infarcted myocardium and its consequences.

Entities:  

Mesh:

Year:  2013        PMID: 23277038     DOI: 10.2741/s359

Source DB:  PubMed          Journal:  Front Biosci (Schol Ed)        ISSN: 1945-0516


  8 in total

1.  mTORC1 signaling is crucial for regulatory T cells to suppress macrophage-mediated inflammatory response after acute myocardial infarction.

Authors:  Keping Yang; Yunfeng Zhang; Chenhong Xu; Xin Li; Dazhu Li
Journal:  Immunol Cell Biol       Date:  2015-10-06       Impact factor: 5.126

2.  Cutting edge: IL-1α is a crucial danger signal triggering acute myocardial inflammation during myocardial infarction.

Authors:  Jérôme Lugrin; Roumen Parapanov; Nathalie Rosenblatt-Velin; Stéphanie Rignault-Clerc; François Feihl; Bernard Waeber; Olivier Müller; Catherine Vergely; Marianne Zeller; Aubry Tardivel; Pascal Schneider; Pal Pacher; Lucas Liaudet
Journal:  J Immunol       Date:  2014-12-10       Impact factor: 5.422

Review 3.  The Role of Damage-Associated Molecular Patterns (DAMPs) in Human Diseases: Part II: DAMPs as diagnostics, prognostics and therapeutics in clinical medicine.

Authors:  Walter G Land
Journal:  Sultan Qaboos Univ Med J       Date:  2015-05-28

Review 4.  Anti-inflammatory strategies for plaque stabilization after acute coronary syndromes.

Authors:  Amos Baruch; Nicholas van Bruggen; Juyong Brian Kim; Joshua E Lehrer-Graiwer
Journal:  Curr Atheroscler Rep       Date:  2013-06       Impact factor: 5.113

5.  Pyrrolidine dithiocarbamate administered during ex-vivo lung perfusion promotes rehabilitation of injured donor rat lungs obtained after prolonged warm ischemia.

Authors:  Cyril Francioli; Xingyu Wang; Roumen Parapanov; Etienne Abdelnour; Jérôme Lugrin; Fabrizio Gronchi; Jean Perentes; Philippe Eckert; Hans-Beat Ris; Lise Piquilloud; Thorsten Krueger; Lucas Liaudet
Journal:  PLoS One       Date:  2017-03-21       Impact factor: 3.240

6.  Matrix Signaling Subsequent to a Myocardial Infarction: A Proteomic Profile of Tissue Factor Microparticles.

Authors:  Derrick Akpalu; Gale Newman; Mark Brice; Mike Powell; Rajesh Singh; Alexander Quarshie; Elizabeth Ofili; James Fonger; Nic Chronos; David Feldman
Journal:  JACC Basic Transl Sci       Date:  2017-10-30

7.  Key role of Extracellular RNA in hypoxic stress induced myocardial injury.

Authors:  Saumya Bhagat; Indranil Biswas; Md Iqbal Alam; Madiha Khan; Gausal A Khan
Journal:  PLoS One       Date:  2021-12-09       Impact factor: 3.240

Review 8.  Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution.

Authors:  Walter Gottlieb Land
Journal:  Mol Diagn Ther       Date:  2020-06       Impact factor: 4.074

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.